TrialThe Lancet. Neurology2023

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.

Vera Bril et al.PubMed ↗Publisher ↗

No numbers read from the abstract.